From Investing.com: 2024-05-03 06:40:54

Shares in Novo Nordisk fell 5.3% after Amgen’s positive interim trial data on its obesity drug. Novo Nordisk was down 4.4% by 1022 GMT, hitting a two-month low. Amgen’s MariTide drug could rival Novo’s Wegovy. Competition in the obesity drug market is heating up, estimated to be worth $100 billion by the end of the decade.



Read more at Investing.com: Novo Nordisk drops 5% after rival Amgen teases weight-loss drug data By Reuters